Iridian Asset Management LLC CT Sells 4,078 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Iridian Asset Management LLC CT trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 7.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 50,965 shares of the medical research company’s stock after selling 4,078 shares during the period. Charles River Laboratories International comprises 2.5% of Iridian Asset Management LLC CT’s holdings, making the stock its 14th biggest position. Iridian Asset Management LLC CT’s holdings in Charles River Laboratories International were worth $9,408,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Versant Capital Management Inc lifted its holdings in Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the last quarter. Wolff Wiese Magana LLC bought a new position in shares of Charles River Laboratories International in the third quarter valued at about $32,000. Pinnacle Bancorp Inc. boosted its holdings in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares during the period. Assetmark Inc. boosted its holdings in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares during the period. Finally, ORG Wealth Partners LLC bought a new position in Charles River Laboratories International in the 4th quarter valued at about $56,000. 98.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CRL. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Evercore ISI raised their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. UBS Group reiterated a “neutral” rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Finally, Morgan Stanley reduced their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $200.79.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $166.32 on Friday. The stock’s 50-day moving average is $181.32 and its 200-day moving average is $194.07. Charles River Laboratories International, Inc. has a 1-year low of $159.65 and a 1-year high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock has a market cap of $8.51 billion, a P/E ratio of 20.82, a price-to-earnings-growth ratio of 6.25 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company’s revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.72 EPS. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 10.17 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).